Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > A patent update

<< Previous

Bullboard Posts

Next >>

Post by Pandoraon Jun 16, 2023 6:21pm

337 Views

Post# 35501133

A patent update

It appears the cannabinoid patent is finally on the move again. It has been given a "Notice of Allowance". This new USPTO site is definitely not as friendly as the old.

Status

Notice of Allowance Mailed -- Application Received in Office of Publications 06/14/2023


06/16/2023	IIFW	Issue Information including classification, examiner, name, claim, renumbering, etc.	3	Preview


06/16/2023	SRFW	Search information including classification, databases and other search related notes	2	Preview


06/16/2023	SRNT	Examiner's search strategy and results	3	Preview


06/16/2023	SRNT	Examiner's search strategy and results	1	Preview

06/16/2023	NOA	Notice of Allowance and Fees Due (PTOL-85)	10	Preview

/ /

16/365,148 | T1081/20069:

METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF A CANNABINOID RECEPTOR AGONIST AND RADIATION THERAPY

Application data

Application type

Utility

Examiner

KARA RENITA MCMILLIAN

Group art unit

1627

Class/subclass

514/185.000

AIA (first inventor to file)

Yes

Entity status

Small

Earliest publication #

US 2019-0290657 A1open_in_new

Earliest publication date

09/26/2019

Assignee for publication

Confirmation #

4146

Intl. registration # (Hague)

Intl. registration publication date

Correspondence address

3000 - CAESAR RIVISE, PC

7 Penn Center, 12th Floor

1635 Market Street

Philadelphia, PA

UNITED STATES

Inventors

Roger DUMOULIN-WHITE

Toronto (CA)
Arkady MANDEL

North York (CA)

Applicants

Theralase Technologies, Inc.

Toronto (CA)